PremiumThe FlyBiomX target adjusted to $21 from $2 at H.C. Wainwright BiomX Announces Positive Phase 2 Trial Results BiomX reports ‘positive’ results from 2 trial evaluating BX211 PremiumCompany AnnouncementsBiomX Inc. Reports Q3 2024 Financial Turnaround BiomX reports Q3 EPS (31c) vs. $1.30 last year PHGE Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumThe FlyBiomX announces 1-for-10 reverse stock split BiomX announces NYSE American acceptance of plan to regain listing compliance BiomX Shareholders Approve Expansion and Governance Changes